Literatur zum CME-Fortbildungsartikel Hormonelle Kontrazeption

  1. Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41(1):3–14CrossRefPubMedPubMedCentral
  2. Dinger JC, Heinemann LA, Kuhl-Habich D (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75(5):344–354CrossRefPubMed
  3. Dinger J, Mohner S, Heinemann K (2016) Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception 93(5):378–385CrossRefPubMed
  4. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344:e2990CrossRefPubMedPubMedCentral
  5. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133(1):32–37CrossRefPubMed
  6. Gaussem P, Alhenc-Gelas M, Thomas JL, Bachelot-Loza C, Remones V, Ali FD et al (2011) Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 105(3):560–567CrossRefPubMed
  7. Dinger J, Do Minh T, Heinemann K (2016) Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 94(4):328–339CrossRefPubMed
  8. Han L, Jensen JT (2015) Does the progestogen used in combined hormonal contraception affect venous thrombosis risk? Obstet Gynecol Clin North Am 42(4):683–698CrossRefPubMed
  9. Blanco-Molina MA, Lozano M, Cano A, Cristobal I, Pallardo LP, Lete I (2012) Progestin-only contraception and venous thromboembolism. Thromb Res 129(5):e257–62
  10. Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME (2018) A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet
  11. Practice Committee of the American Society for Reproductive Medicine (2017) Electronic address Aao, Practice Committee of the American Society for Reproductive M. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 107(1):43–51
  12. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344(8935):1453–1457CrossRefPubMed
  13. Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B et al (2016) Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 127(11):1417–1425CrossRefPubMedPubMedCentral
  14. Medical Eligibility Criteria for Contraceptive Use, 2015. 5th edition. Geneva: World Health Organization
  15. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR (2010) The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 30(11):2297–2300CrossRefPubMed
  16. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366(24):2257–2266CrossRefPubMed
  17. Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M (2013) Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 27(1):35–45CrossRefPubMed
  18. Mant J, Painter R, Vessey M (1998) Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol 105(8):890–896CrossRefPubMed
  19. D’Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S (1994) Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health 48(3):324–325CrossRefPubMedPubMedCentral
  20. Lidegaard O (1995) Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 102(2):153–159CrossRefPubMed
  21. Dilshad H, Yousuf RI, Shoaib MH, Jamil S, Khatoon H (2016) Cardiovascular disease risk associated with the long-term use of depot medroxyprogesterone acetate. Am J Med Sci 352:487–492PubMed
  22. Mensink GB, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C (2013) Overweight and obesity in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(5–6):786–794CrossRefPubMed
  23. Horton LG, Simmons KB, Curtis KM (2016) Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 94(6):590–604CrossRefPubMed
  24. Brunner Huber LR, Hogue CJ, Stein AD, Drews C, Zieman M (2006) Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol 16(8):637–643CrossRefPubMed
  25. Brunner LR, Hogue CJ (2005) The role of body weight in oral contraceptive failure: results from the 1995 national survey of family growth. Ann Epidemiol 15(7):492–499CrossRefPubMed
  26. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR (2005) Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 105(1):46–52CrossRefPubMed
  27. Holt VL, Cushing-Haugen KL, Daling JR (2002) Body weight and risk of oral contraceptive failure. Obstet Gynecol 99(5 Pt 1):820–827PubMed
  28. Vessey M (2001) Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann Reprod Health Care 27(2):90–91CrossRefPubMed
  29. Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A et al (2013) Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2013(4):CD008452
  30. McNicholas C, Zhao Q, Secura G, Allsworth JE, Madden T, Peipert JF (2013) Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 121(3):585–592CrossRefPubMedPubMedCentral
  31. Jatlaoui TC, Curtis KM (2016) Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review. Contraception. https://​doi.​org/​10.​1016/​j.​contraception.​2016.​05.​002
  32. Black A, Guilbert E, Co A, Costescu D, Dunn S, Fisher W, et al (2015) Canadian Contraception Consensus (Part 2 of 4). J Obstet Gynaecol Can 37(11):1033–1039CrossRefPubMed
  33. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4–14CrossRefPubMed
  34. Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D et al (1997) A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20(3):330–335CrossRefPubMed
  35. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B et al (1992) Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35(10):967–972CrossRefPubMed
  36. Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373(9677):1773–1779CrossRefPubMed
  37. Beydoun HA, Beydoun MA, Tamim H (2009) How does gestational diabetes affect postpartum contraception in nondiabetic primiparous women? Contraception 79(4):290–296CrossRefPubMed
  38. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B et al (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323(20):1375–1381CrossRefPubMed
  39. Lopez LM, Grimes DA, Schulz KF (2014) Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014(4):CD006133
  40. Troisi RJ, Cowie CC, Harris MI (2000) Oral contraceptive use and glucose metabolism in a national sample of women in the united states. Am J Obstet Gynecol 183(2):389–395CrossRefPubMed
  41. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE (1994) Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 271(14):1099–1102CrossRefPubMed
  42. Klein BE, Moss SE, Klein R (1990) Oral contraceptives in women with diabetes. Diabetes Care 13(8):895–898CrossRefPubMed
  43. Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM et al (2005) Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 28(8):1988–1994CrossRefPubMed
  44. Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P et al (1982) Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25(6):618–623CrossRefPubMed
  45. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550–2558CrossRefPubMed
  46. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353(24):2539–2549CrossRefPubMed
  47. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485CrossRefPubMedPubMedCentral
  48. Johnston RD, Logan RF (2008) What is the peak age for onset of IBD? Inflamm Bowel Dis 14(Suppl 2):S4–S5CrossRefPubMed
  49. Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF (2014) Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 8(6):469–479CrossRefPubMed
  50. Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375(9715):657–663CrossRefPubMed
  51. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK (2016) U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(3):1–103. https://​doi.​org/​10.​15585/​mmwr.​rr6503a1
  52. Zapata LB, Paulen ME, Cansino C, Marchbanks PA, Curtis KM (2010) Contraceptive use among women with inflammatory bowel disease: A systematic review. Contraception 82(1):72–85CrossRefPubMed
  53. Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, Feychting M et al (2005) Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer 117(6):996–1001CrossRefPubMed
  54. Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80(1):1–7CrossRefPubMed
  55. Lusis EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine MR, Paulus W et al (2012) Meningiomas in pregnancy: a clinicopathologic study of 17 cases. Neurosurgery 71(5):951–961CrossRefPubMed
  56. Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, et al (2018) Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neurooncol 136(2):327–333CrossRefPubMed
  57. Niedziela N, Adamczyk-Sowa M, Pierzchala K (2014) Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci 124(5):322–330CrossRefPubMed
  58. Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C et al (2009) The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement. J Neurol Sci 286(1–2):114–118CrossRefPubMed
  59. Vessey MP, Lawless M (1984) The Oxford-Family Planning Association contraceptive study. Clin Obstet Gynaecol 11(3):743–757PubMed
  60. Thorogood M, Hannaford PC (1998) The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 105(12):1296–1299CrossRefPubMed
  61. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A (2000) Oral contraceptives and the incidence of multiple sclerosis. Neurology 55(6):848–854CrossRefPubMed
  62. Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62(9):1362–1365CrossRefPubMed
  63. Zapata LB, Oduyebo T, Whiteman MK, Houtchens MK, Marchbanks PA, Curtis KM (2016) Contraceptive use among women with multiple sclerosis: a systematic review. Contraception. https://​doi.​org/​10.​1016/​j.​contraception.​2016.​07.​013
  64. Ball SJ, Pereira G, Jacoby P, de Klerk N, Stanley FJ (2014) Re-evaluation of link between interpregnancy interval and adverse birth outcomes: retrospective cohort study matching two intervals per mother. BMJ 349:g4333CrossRefPubMedPubMedCentral
  65. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143(10):697–706CrossRefPubMed
  66. Jackson E, Curtis KM, Gaffield ME (2011) Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 117(3):691–703CrossRefPubMed
  67. Kapp N, Curtis KM (2010) Combined oral contraceptive use among breastfeeding women: a systematic review. Contraception 82(1):10–16CrossRefPubMed
  68. Kapp N, Curtis K, Nanda K (2010) Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception 82(1):17–37CrossRefPubMed
  69. Lopez LM, Grey TW, Stuebe AM, Chen M, Truitt ST, Gallo MF (2015) Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2015(3):CD003988
  70. Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM (2016) Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. Contraception 94(3):262–274CrossRefPubMed
  71. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312(7023):83–88CrossRefPubMedPubMedCentral
  72. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346(8990):1589–1593CrossRefPubMed
  73. de Bastos M et al (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014(3):CD010813
  74. Grimes DA, Stuart GS, Levi EE (2012) Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol 120(4):889–895CrossRefPubMed
  75. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM (2016) Progestin-only contraception and thromboembolism: A systematic review. Contraception. https://​doi.​org/​10.​1016/​j.​contraception.​2016.​04.​014
  76. Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F (2006) Association of meningioma with reproductive factors. Int J Cancer 119(5):1152–1157CrossRefPubMed
  77. Custer B, Longstreth WT Jr., Phillips LE, Koepsell TD, Van Belle G (2006) Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6:152CrossRefPubMedPubMedCentral
  78. Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M et al (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164(7):629–636CrossRefPubMed
  79. Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A (2010) Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control 21(12):2149–2156CrossRefPubMed

Artikel teilen

Kommentare (0)

Kommentar schreiben

Die Meinung und Diskussion unserer Nutzer ist ausdrücklich erwünscht. Bitte achten Sie im Sinne einer angenehmen Kommunikation auf unsere Netiquette und Nutzungsbedingungen. Vielen Dank!

* Pflichtfeld

Das PTA Magazin

DAS PTA MAGAZIN wendet sich an das Fachpersonal in der öffentlichen Apotheke, wobei die Zeitschrift insbesondere auf das berufliche Informationsbedürfnis der Pharmazeutisch-Technischen Assistentin eingeht.


Springer Medizin

Springermedizin.de ist das Fortbildungs- und Informationsportal für Ärzte und Gesundheitsberufe, das für Qualität, Aktualität und gesichertes Wissen steht. Das umfangreiche CME-Angebot und die gezielte Berichterstattung für alle Fachgebiete unterstützen den Arbeitsalltag.



Mit unserem Newsletter erhalten Sie Fachinformationen direkt in Ihr Postfach – wöchentlich und kostenlos.